Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
William Plovanic joined Canaccord in 2007 as a managing director, medical technology equity research analyst. He has been a publishing sell-side analyst with coverage of medical devices for over 15 years. Plovanic's areas of coverage include orthopedics, diabetes, obesity, neuro-technologies, dialysis, aesthetics and general surgery. In 2009 he was ranked as the #2 Earnings Estimator for health care equipment & supplies by Starmine. Furthermore, in 2003 and 2004, he was selected as a Wall Street Journal "All Star" analyst in the medical device sector and in 2002 was named the #1 ranked analyst by Starmine for stock picking and performance in the medical technology sector. He is a frequent presenter at medical and industry meetings. Prior to Canaccord, Mr. Plovanic was a managing director and senior research analyst at First Albany (now Gleacher & Company). Previously, he worked at PMG Capital covering medical devices and products. Plovanic also worked as director of research for the Capital Markets Division of LaSalle St. Securities Inc., where he focused on the small-cap healthcare, technology and biotechnology industries. He graduated from Bradley University with a Bachelor of Science in finance and is a Chartered Financial Analyst.
What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic (2/21/13) Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation.
Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects (6/21/12) Every year, top researchers and physicians meet at the American Diabetes Association Scientific Sessions. This year, Canaccord Genuity Analyst and Managing Director William Plovanic reported back on promising developments and what they could mean for the companies behind them. In this interview with The Life Sciences Report, he explains why he is so positive on the space in general and about certain companies in particular.
Choose Medical Technology Stocks Carefully: William Plovanic (3/15/12) The dart board will not help in picking medical technology stocks. Analyst and Managing Director William Plovanic of Canaccord Genuity focuses on the musculoskeletal/orthopedic sector, which is sensitive to factors beyond just the unmet needs of patients. Economic and regulatory dynamics make it difficult to predict growth in medtech, but in this exclusive interview with The Life Sciences Report, veteran analyst Plovanic delivers both ideas and names that could generate excellent returns for investors.
"If approved by the FDA, MDT's MiniMed 530G system will be the only integrated insulin pump and continuous glucose monitor in the U.S. that automatically suspends insulin delivery if the sensor glucose value is equal to or below the low threshold value." (6/21/12) Medtronic Inc. - The Life Sciences Report Interview with William Plovanic More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >